Evidence map›Paper›PMID 28324149›Full record

ArticleZeitschrift fur Rheumatologie2018

[Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons].

K Albrecht, A Luque Ramos, J Callhoff, F Hoffmann, K Minden, A Zink

Abstract read
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

K AlbrechtProgrammbereich Epidemiologie, Deutsches Rheumaforschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. albrecht@drfz.de.
A Luque RamosDepartment für Versorgungsforschung, Carl von Ossietzky Universität Oldenburg, Oldenburg, Deutschland.
J CallhoffProgrammbereich Epidemiologie, Deutsches Rheumaforschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
F HoffmannDepartment für Versorgungsforschung, Carl von Ossietzky Universität Oldenburg, Oldenburg, Deutschland.
K MindenProgrammbereich Epidemiologie, Deutsches Rheumaforschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
A ZinkProgrammbereich Epidemiologie, Deutsches Rheumaforschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
Charité - Universitätsmedizin Berlin · DECarl von Ossietzky Universität Oldenburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHealthcare of patients with rheumatoid arthritis (RA) in Germany has mainly been evaluated in the past in RA cohorts from specialized arthritis centers. This study investigated rheumatological care on a population basis, using claims data from a nationwide statutory health insurance fund (BARMER GEK) in combination with patient-reported outcomes from a questionnaire survey of insured persons with RA.

methodsData from insurants aged 18-79 years with M05 (seropositive RA) or M06 (other RA, ICD-10) diagnoses were analyzed concerning diagnostics, medication and prescribing physician. A 31-item questionnaire covering patient reported diagnosis, healthcare utilization and burden of illness was sent to a stratified random sample of 6193 insured persons. Data from the respondents regarding rheumatological care and disease status were evaluated.

resultsIn 2013 and 2014, a total of 96,921 adults with M05 or M06 diagnosis were insured. The questionnaire was answered by 51% of the sample and of these 81% confirmed the RA diagnosis. RA had been diagnosed by a rheumatologist in 59% of the cases, 70% reported moderate to severe pain and 46% had functional disability. Between at least 40% (claims data) and up to 68% (respondents) were in specialized rheumatological care. Treatment with disease-modifying antirheumatic drugs (DMARDs) was 61% (claims data) and 63% (respondents) in persons in rheumatological care but only 18% outside rheumatological care.

conclusionThe results indicate that specialized rheumatological care is required to provide adequate treatment for patients with RA in Germany. Patients with higher age and patients with M06 diagnosis had less drug prescriptions and were less frequently treated by rheumatologists.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidInformation Storage and RetrievalAdolescentAdultAgedAmbulatory CareGermanyHumansInsurance, HealthMiddle AgedSurveys and QuestionnairesYoung AdultAntirheumatic AgentsDiagnosticsDisease burdenDrug treatmentHealth careRheumatoid arthritis

Identifiers

PMID28324149
OpenAlexW2602256766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.